

Serena Vettori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/295600/publications.pdf>

Version: 2024-02-01

52
papers

2,576
citations

236612

25
h-index

189595

50
g-index

52
all docs

52
docs citations

52
times ranked

3359
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
2	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1898-1904.	0.5	165
3	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	1.1	158
4	Role of MicroRNAs in Fibrosis. <i>Open Rheumatology Journal</i> , 2012, 6, 130-139.	0.1	144
5	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.5	142
6	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
7	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq1 1 0.784314 rgBT /Overlock 11</i>	2.5	107
8	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
9	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.5	96
10	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.5	82
11	Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. <i>Rheumatology</i> , 2011, 50, 317-323.	0.9	61
12	Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. <i>Journal of Clinical Immunology</i> , 2014, 34, 663-668.	2.0	61
13	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
14	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.5	56
15	Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 437-444.	1.6	51
16	Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity. <i>Arthritis Care and Research</i> , 2014, 66, 1520-1527.	1.5	48
17	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1697-1705.	0.5	48
18	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 303-310.	0.5	45

#	ARTICLE	IF	CITATIONS
19	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	2.5	43
20	High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e105008.	1.1	39
21	Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. <i>Arthritis Research and Therapy</i> , 2013, 15, R63.	1.6	38
22	Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 485-489.	0.6	31
23	Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. <i>Arthritis Research and Therapy</i> , 2012, 14, R188.	1.6	31
24	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
25	Association between a stromal cell-derived factor 1 (<i>SDF-1/CXCL12</i>) gene polymorphism and microvascular disease in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 408-411.	0.5	29
26	The Concept of Early Systemic Sclerosis Following 2013 ACREULAR Criteria for the Classification of Systemic Sclerosis. <i>Current Rheumatology Reviews</i> , 2014, 10, 38-44.	0.4	26
27	Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. <i>Scientific Reports</i> , 2019, 9, 9468.	1.6	26
28	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1210-1215.	0.5	25
29	Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 23.	1.0	22
30	Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. <i>Clinical Rheumatology</i> , 2016, 35, 1733-1742.	1.0	22
31	Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 673-680.	1.6	21
32	The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. <i>Arthritis Research and Therapy</i> , 2017, 19, 133.	1.6	21
33	Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. <i>Clinical Rheumatology</i> , 2018, 37, 1239-1247.	1.0	21
34	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. <i>British Journal of Pharmacology</i> , 2020, 177, 4296-4309.	2.7	19
35	Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role?. <i>Rheumatology</i> , 2010, 49, 1257-1266.	0.9	16
36	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. <i>International Journal of Cardiology</i> , 2016, 223, 385-389.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Non-Hodgkinâ€™s lymphoma in systemic sclerosis: case and literature review. <i>Clinical Rheumatology</i> , 2010, 29, 1-6.	1.0	14
38	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	0.9	14
39	Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2015, 181, 100-109.	1.1	13
40	Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. <i>Medicine (United States)</i> , 2016, 95, e3931.	0.4	13
41	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
42	Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. <i>Patient Related Outcome Measures</i> , 2017, Volume 8, 7-13.	0.7	11
43	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-6.	0.8	11
44	CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	10
45	T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 220.	2.2	10
46	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5â€™years from diagnosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 57-65.	1.0	8
47	Serum CXCL4 increase in primary Sjögrenâ€™s syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement. <i>Clinical Rheumatology</i> , 2016, 35, 2591-2596.	1.0	6
48	Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association. <i>PLoS ONE</i> , 2018, 13, e0210023.	1.1	5
49	Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. <i>Clinical Rheumatology</i> , 2016, 35, 1985-1991.	1.0	4
50	MiRs in RA: possible biomarkers and therapeutic targets. <i>Arthritis Research and Therapy</i> , 2012, 14, .	1.6	1
51	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial compared with healthy reference subjects. <i>Respiratory Research</i> , 2022, 23, .	1.4	1
52	A7.3â€™...Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A48.3-A49.	0.5	0